

TITAN INTERNATIONAL INC  
Form SC 13D/A  
October 04, 2016  
Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D**

**[Rule 13d-101]**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED**

**PURSUANT TO § 240.13d-1(a) AND AMENDMENTS**

**THERE TO FILED PURSUANT TO § 240.13d-2(a)**

**(Amendment No. 8)\***

**Titan International, Inc.**  
**(Name of Issuer)**

**Common Stock, No Par Value Per Share**  
**(Title of Class of Securities)**

**88830M102**  
**(CUSIP Number)**

**Janet Yeung**

**MHR Fund Management LLC**

**1345 Avenue of the Americas, 42nd Floor**

**New York, New York 10105**

**(212) 262-0005**

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**September 29, 2016**

**(Date of Event which Requires Filing of this Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box " ".

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 11 Pages)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



**Table of Contents**

CUSIP No. 88830M102

**13D**

Page 2 of 9 Pages

**1** NAMES OF REPORTING PERSONS

**2** MHR INSTITUTIONAL PARTNERS III LP  
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a)  (b)

**3** SEC USE ONLY

**4** SOURCE OF FUNDS (SEE INSTRUCTIONS)

**5** WC  
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

**6** CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF **7** SOLE VOTING POWER  
SHARES

BENEFICIALLY 7,200,427  
**8** SHARED VOTING POWER

OWNED BY

EACH 0  
REPORTING **9** SOLE DISPOSITIVE POWER

PERSON

WITH 7,200,427  
**10** SHARED DISPOSITIVE POWER

0

**11** AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

7,200,427

**12** CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ..

**13** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13.3%

**14** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

PN

**Table of Contents**

CUSIP No. 88830M102

**13D**

Page 3 of 9 Pages

**1 NAMES OF REPORTING PERSONS**

**2 MHR INSTITUTIONAL ADVISORS III LLC  
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)**

(a)  (b)

**3 SEC USE ONLY**

**4 SOURCE OF FUNDS (SEE INSTRUCTIONS)**

**5 AF  
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)**

**6 CITIZENSHIP OR PLACE OF ORGANIZATION**

Delaware

NUMBER OF **7** SOLE VOTING POWER  
SHARES

BENEFICIALLY 7,200,427  
**8** SHARED VOTING POWER

OWNED BY

EACH 0  
REPORTING **9** SOLE DISPOSITIVE POWER

PERSON

WITH 7,200,427  
**10** SHARED DISPOSITIVE POWER

0

**11** AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

7,200,427

**12** CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ..

**13** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13.3%

**14** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO

**Table of Contents**

CUSIP No. 88830M102

**13D**

Page 4 of 9 Pages

**1 NAMES OF REPORTING PERSONS**

**2 MHR FUND MANAGEMENT LLC  
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)**

(a)  (b)

**3 SEC USE ONLY**

**4 SOURCE OF FUNDS (SEE INSTRUCTIONS)**

**5 AF  
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)**

**6 CITIZENSHIP OR PLACE OF ORGANIZATION**

Delaware

NUMBER OF **7** SOLE VOTING POWER  
SHARES

BENEFICIALLY 8,005,000  
**8** SHARED VOTING POWER

OWNED BY

EACH 0  
REPORTING **9** SOLE DISPOSITIVE POWER

PERSON

WITH 8,005,000  
**10** SHARED DISPOSITIVE POWER



0

**11** AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

8,005,000

**12** CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ..

**13** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

14.8%

**14** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO

**Table of Contents**

CUSIP No. 88830M102

**13D**

Page 5 of 9 Pages

**1** NAMES OF REPORTING PERSONS

MHR HOLDINGS LLC

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a)  (b)

**3** SEC USE ONLY

**4** SOURCE OF FUNDS (SEE INSTRUCTIONS)

AF

**5** CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

**6** CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF **7** SOLE VOTING POWER

SHARES

BENEFICIALLY 8,005,000

**8** SHARED VOTING POWER

OWNED BY

EACH

0

REPORTING **9** SOLE DISPOSITIVE POWER

PERSON

WITH

8,005,000

**10** SHARED DISPOSITIVE POWER

0

**11** AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

8,005,000

**12** CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ..

**13** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

14.8%

**14** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO

**Table of Contents**

CUSIP No. 88830M102

**13D**

Page 6 of 9 Pages

**1** NAMES OF REPORTING PERSONS

MARK H. RACHESKY, M.D.

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a)  (b)

**3** SEC USE ONLY

**4** SOURCE OF FUNDS (SEE INSTRUCTIONS)

AF

**5** CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

**6** CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America

NUMBER OF **7** SOLE VOTING POWER

SHARES

BENEFICIALLY 8,064,000

**8** SHARED VOTING POWER

OWNED BY

EACH

0

REPORTING **9** SOLE DISPOSITIVE POWER

PERSON

WITH 8,064,000

**10** SHARED DISPOSITIVE POWER

0

**11** AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

8,064,000

**12** CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ..

**13** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

14.90%

**14** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN; HC

**Table of Contents**

Page 7 of 9 Pages

**TABLE OF CONTENTS**

|  |   |
|--|---|
| <u>Item 4.</u> Purpose of Transaction  | 8 |
| <u>Item 5.</u> Interest in Securities of the Issuer  | 8 |
| <u>Item 6.</u> Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer | 8 |
| <u>Item 7.</u> Material to Be Filed as Exhibits  | 8 |
| <u>Signatures</u>  | 9 |

---

**Table of Contents**

Page 8 of 9 Pages

This statement on Schedule 13D (this Statement ) amends and supplements, as Amendment No. 8, the Schedule 13D filed on January 21, 2014 (the Initial Schedule 13D ), which was amended on February 20, 2014 by Amendment No. 1 to the Initial Schedule 13D ( Amendment No. 1 ), on February 27, 2014 by Amendment No. 2 to the Initial Schedule 13D ( Amendment No. 2 ), and on April 24, 2014 by Amendment No. 3 to the Initial Schedule 13D ( Amendment No. 3 ), and on April 30, 2014 by Amendment No. 4 to the Initial Schedule 13D ( Amendment No. 4 ), on July 31, 2014 by Amendment No. 5 to the initial Schedule 13D ( Amendment No. 5 ), on December 10, 2014 by Amendment No. 6 to the initial Schedule 13D ( Amendment No. 6 ), and on February 29, 2016 by Amendment No. 7 to the Initial Schedule 13D ( Amendment No. 7 ) and, together with the Initial Schedule 13D and Amendment No. 1 through Amendment No. 6, the Schedule 13D ), and relates to shares of common stock, no par value per share (the Common Stock ), of Titan International, Inc. (the Issuer ). Capitalized terms used in this Statement but not defined herein shall have the respective meanings given to such terms in Amendment No. 7.

**Item 4 Purpose of Transaction**

Item 4 is hereby amended by adding the following:

On September 29, 2016, the Reporting Persons (together with certain of their affiliates, MHR ), Michael Sirignano and the Issuer entered into an Audit Committee Observer Agreement (the Observer Agreement ) that grants MHR the right to designate an observer to the Audit Committee of the Board of Directors of the Issuer (the Audit Committee ) so long as MHR beneficially owns at least the lesser of (i) 8,005,000 shares of Common Stock and (ii) 10% of the issued and outstanding shares of Common Stock. Pursuant to the Observer Agreement, MHR has designated Michael Sirignano, a principal of Fund Management, as the initial observer to the Audit Committee, and is entitled to direct the replacement of the observer for any reason and at any time.

The foregoing description of the Observer Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Observer Agreement, a copy of which is filed as Exhibit 1 to this Statement and is incorporated by reference herein.

**Item 5 Interest in Securities of the Issuer**

Item 5(a)(ix) and 5(b)(ix) are hereby amended by deleting such Items in their entirety and replacing them with the following:

The percentages set forth below are calculated based on information contained in the Issuer's Form 10-Q for the quarterly period ended June 30, 2016, which disclosed that there were 54,046,512 shares of Common Stock outstanding as of July 20, 2016.

(a) (ix) Dr. Rachesky may be deemed to be the beneficial owner of 8,064,000 shares of Common Stock (approximately 14.90% of the total number of shares of Common Stock outstanding, calculated in accordance with Rule 13d-3(d)(1)(i) under the Act). This number consists of (a) all of the shares of Common Stock otherwise described in this Item 5(a) by virtue of Dr. Rachesky's position as the managing member of each of MHRC, Institutional Advisors III and MHR Holdings and (b) stock options to purchase 59,000 shares of Common Stock held directly.

(b) (ix) Dr. Rachesky may be deemed to have (x) the sole power to direct the disposition of 8,064,000 shares of Common Stock which may be deemed to be beneficially owned by Dr. Rachesky as described above, and (y) the sole power to direct the voting of 8,064,000 shares of Common Stock which may be deemed to be beneficially owned by Dr. Rachesky as described above.

**Item 6 Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer**

Item 6 is hereby amended by adding the following:

The information set forth in Item 4 above is incorporated into this Item 6 by reference.

**Item 7 Material to Be Filed as Exhibits**

| Exhibit No. | Description  |
|-------------|--|
| 1           | Audit Committee Observer Agreement, dated as of September 29, 2016, by and among the Issuer and Michael Sirignano, Mark H. Rachesky, M.D., MHR Holdings LLC, MHR Fund Management LLC, MHR Institutional Advisors III LLC, MHR Advisors LLC, MHRC LLC, MHR Institutional Partners III LP, MHR Capital Partners Master Account LP and MHR Capital Partners (100) LP (incorporated by reference to Exhibit 10 to the Issuer's Current Report on Form 8-K filed on October 3, 2016). |



**SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

Date: October 4, 2016

MHR INSTITUTIONAL PARTNERS III LP

By: MHR Institutional Advisors III LLC,  
its General Partner

By: /s/ Janet Yeung  
Name: Janet Yeung  
Title: Authorized Signatory

MHR INSTITUTIONAL ADVISORS III LLC

By: /s/ Janet Yeung  
Name: Janet Yeung  
Title: Authorized Signatory

MHR FUND MANAGEMENT LLC

By: /s/ Janet Yeung  
Name: Janet Yeung  
Title: Authorized Signatory

MHR HOLDINGS LLC

By: /s/ Janet Yeung  
Name: Janet Yeung  
Title: Authorized Signatory

MARK H. RACHESKY, M.D.

By: /s/ Janet Yeung, Attorney in Fact